Fulcrum Therapeutics, Inc.
FULC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FULC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FULC
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases, with its lead product candidate pociredir (formerly losmapimod) in clinical development.
Key risk: Need for additional capital
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials for Fulcrum Therapeutics, Inc..
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases, with its lead product candidate pociredir (formerly losmapimod) in clinical development.
- Fulcrum Therapeutics is advancing pociredir (formerly losmapimod) in clinical trials for genetically defined rare diseases [sec · filed 2019-11-14].
- As of June 30, 2026, the company reported cash and equivalents of $48.5M and a net loss of $26.2M for the quarter [sec].
- The company had an accumulated deficit of $613.2 million as of March 31, 2026 [sec_mda · as of 2026-04-27].
- Fulcrum is also pursuing preclinical development of FTX-6058 and other early-stage programs [sec · filed 2019-11-14].
What works
- Fulcrum has a focused strategy on genetically defined rare diseases, which may allow for more targeted and potentially efficient clinical development [sec_mda · as of 2026-04-27].
- The company continues to advance pociredir into later-stage trials, indicating progress in its lead program [sec_mda · as of 2026-04-27].
What to weigh
- Fulcrum has a significant accumulated deficit of $613.2 million as of March 31, 2026, reflecting ongoing operating losses [sec_mda · as of 2026-04-27].
- The company expects expenses and operating losses to increase over the next several years as it advances its pipeline [sec_mda · as of 2026-04-27].
- Fulcrum will need substantial additional funding to continue operations; if unable to raise capital, it may be forced to delay or reduce programs [sec · filed 2019-11-14].
From the filings
Quoted directly from source documents.
Fulcrum had an accumulated deficit of $613.2 million as of March 31, 2026.
“As of March 31, 2026, we had an accumulated deficit of $613.2 million.”
SEC MD&A · April 27, 2026
The company expects expenses and operating losses to increase over the next several years.
“We expect our expenses and operating losses will increase over the next several years in connection with our ongoing activities, as we: • continue our clinical development of pociredir and advance the program into a later stage trial;”
SEC MD&A · April 27, 2026
Fulcrum will need substantial additional funding to continue operations.
“We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product d”
SEC filings · November 14, 2019
Risks & what to watch (3)›
Key risks
- Need for additional capital — Fulcrum requires substantial funding to continue operations; failure to raise capital may force program delays or reductions [sec · filed 2019-11-14].
- History of operating losses — The company has an accumulated deficit of $613.2M and expects losses to increase, with no guarantee of profitability [sec_mda · as of 2026-04-27].
- Clinical development risks — Pociredir and other candidates are in clinical or preclinical stages and may fail to demonstrate safety or efficacy [sec · filed 2019-11-14].
What to watch
- Progress of pociredir clinical trials and advancement into later-stage studies [sec_mda · as of 2026-04-27].
- Updates on FTX-6058 preclinical development and potential IND filing [sec · filed 2019-11-14].
- Cash runway and any future capital raises, given $48.5M cash as of June 30, 2026 [sec].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Fulcrum Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Fulcrum Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
24.5 months
D/E 0.04 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
6 buys · 1 sell (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
163
Total value held
$451.4M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 6,561,111 | $50.3M |
| ra capital management, l.p. | 6,053,960 | $46.4M |
| blackrock, inc. | 5,390,593 | $41.3M |
| vanguard capital management llc | 5,385,896 | $41.3M |
| braidwell lp | 3,134,922 | $24.0M |
| balyasny asset management l.p. | 2,179,946 | $16.7M |
| point72 asset management, l.p. | 2,074,855 | $15.9M |
| gsk plc | 1,785,714 | $13.7M |
| jones hill capital lp | 1,771,926 | $13.6M |
| d. e. shaw & co., inc. | 1,623,281 | $12.5M |
Showing top 10 of 163 institutional holders of Fulcrum Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 12.1%
- Days to cover
- 8.1
- Shares short
- 7,967,121
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FULC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Fulcrum Therapeutics, Inc.?
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases, with its lead product candidate pociredir (formerly losmapimod) in clinical development.
What is Fulcrum Therapeutics, Inc.'s lead drug candidate?
Fulcrum Therapeutics, Inc.'s most advanced tracked candidate is losmapimod (Phase 2) for Facioscapulohumeral Muscular Dystrophy 1; Facioscapulohumeral Muscular Dystrophy (FSHD).
Who is the CEO of Fulcrum Therapeutics, Inc.?
Mr. Alexander C. Sapir is the chief executive officer of Fulcrum Therapeutics, Inc. (FULC).
Where is Fulcrum Therapeutics, Inc. headquartered?
Fulcrum Therapeutics, Inc. (FULC) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Fulcrum Therapeutics, Inc. focus on?
Fulcrum Therapeutics, Inc. develops therapies across Oncology, Rare Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.